drugset / Trial / NCT01134341
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.
Timeline
- Start
- 2010-03
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexarotene | Small molecule | 150 mg | Oral |
| Subject | Bexarotene | Small molecule | 300 mg | Oral |
| Subject | Pralatrexate | Other / unclassified | 10 mg/m2 | Intravenous |
| Subject | Pralatrexate | Other / unclassified | 15 mg/m2 | Intravenous |